Core Insights - Gelteq Limited announced positive results from a preclinical study demonstrating that its proprietary oral gel platform significantly enhances the absorption and bioavailability of cannabidiol (CBD) compared to an existing FDA-approved oil-based product [1][2] Group 1: Product Development and Efficacy - Gelteq's formulation achieved over a 22% increase in bioavailability despite having a lower concentration of CBD, indicating more efficient uptake of lipophilic cannabinoid molecules [2] - The oral gel platform offers a safer, more predictable, and convenient alternative to traditional CBD products, addressing issues such as variable dosing and slow onset [3][4] - The gel format allows for pre-measured and precise dosing, reducing the need for droppers and food timing, which enhances treatment consistency [4] Group 2: Market Opportunities - The results create a pathway for expedited market launch of new medicinal cannabis products in Australia through the Special Access Scheme (SAS), potentially allowing earlier patient access and faster market entry [2][8] - Gelteq's oral gel platform could enable partnerships with medicinal cannabis companies without the need for additional studies, accelerating licensing and co-development opportunities across various cannabinoid-based products [6][7] Group 3: Industry Positioning - The improved bioavailability of cannabinoids positions Gelteq as a leader in advanced oral delivery technologies, supporting the next generation of medicinal cannabis products tailored to patient needs [9] - The medicinal cannabis market is rapidly growing, with product differentiation increasingly driven by delivery innovation, which Gelteq's platform is well-positioned to capitalize on [6]

Core Viewpoint - 2025 has been a transformational year for Nasus Pharma, marked by significant clinical advancements and the development of innovative intranasal products aimed at treating emergency medical conditions [2][3]. Group 1: Clinical Development - Nasus Pharma presented integrated data from two early clinical trials of NS002, an intranasal epinephrine powder formulation, which showed potential for faster and higher absorption compared to traditional injectable epinephrine [3]. - The company received authorization from Health Canada to initiate a Phase 2 clinical study of NS002, with the first patient dosed in an open-label trial comparing NS002 to EpiPen® [6]. - An interim analysis of the Phase 2 clinical study is expected to be reported in early Q1 2026 [8]. Group 2: Financial Position - The company successfully completed its initial public offering in August 2025, raising $10 million in gross proceeds, which strengthened its financial position [4]. Group 3: Collaborations and Technology - Nasus Pharma expanded collaboration agreements with Aptar France S.A.S. and AptarGroup Inc. to support the clinical development and commercialization of NS002, leveraging proven technology for faster market access [5]. - The proprietary Nasax powder technology offers a fast, needle-free, and portable method for delivering life-saving medications, with broad potential applications in emergency care [8]. Group 4: Future Plans - The company aims to initiate first-in-human studies for one or two additional pipeline products during 2026, while continuing to advance the NS002 program [7]. - Key regulatory and clinical milestones for NS002 include a planned IND submission in Q3 2026 and the initiation of pivotal and pediatric studies in Q3 and Q4 2026, respectively [8].

Core Viewpoint - Polyrizon Ltd. has initiated preclinical studies for intranasal Benzodiazepines (BZDs) aimed at improving emergency treatment options for acute repetitive seizures and status epilepticus using its proprietary drug delivery platform [1][5][8]. Company Summary - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels and drug delivery systems, including its Trap and Target™ (T&T) platform for administering BZDs [1][8]. - The company is collaborating with Professor Fabio Sonvico from the University of Parma, an expert in intranasal drug delivery solutions, to conduct these preclinical studies [4]. Industry Summary - The global acute repetitive seizures market was valued at approximately USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030 [2]. - The global epilepsy treatment devices market was valued at around USD 526.8 million in 2023 and is expected to reach approximately USD 787.3 million by 2033, growing at a CAGR of about 4.1% from 2024 to 2033 [3].